Body Handbook Catalogue Profile Ranking
Screening BODY HANDBOOK
Screening Β· Β§145
Teplizumab and T1D Screening
Type 1 diabetes used to announce itself in the ER: a confused, dehydrated child, suddenly insulin-dependent for life. It no longer has to. A blood test, free for relatives of anyone with T1D, spots the autoimmune attack years before symptoms. Two or more islet autoantibodies mean the disease is essentially inevitable Ziegler et al. 2013 β€” but knowing early keeps the diagnosis out of intensive care, and for one narrow group, a single drug course buys years before it arrives.
Screen Β· Once Evidence Moderate Chapter Screening

The attack leaves a trace in the blood. T1D is autoimmune: T cells kill the insulin-making beta cells over months to years, and by the time a child is thirsty and losing weight, most of those cells are gone. Long before that, the blood carries islet autoantibodies. Two or more persistent ones in childhood mean the attack has begun, and only the timing of diabetes is still open 1.

Teplizumab is the first drug that changes the clock. It's an antibody that quiets the T cells doing the killing. Given as one 14-day course at the pre-diabetic Stage 2, it pushed the median time to clinical diabetes from 24.4 to 48.4 months 2. Longer follow-up widened the gap to about a 32-month median delay 3.

Screening does most of the work on its own. About one in four US kids first learns they have T1D during a dangerous crisis called DKA. Kids found through screening arrive that way roughly one time in twenty instead 4. The diagnosis still comes, but as a clinic appointment instead of an ambulance.

If a relative has T1D, request the free screen first. The drug decision comes later, and only for a few.

The teplizumab course itself is 14 consecutive weekdays of infusions at a specialty center, about two hours each, after baseline labs 5. One course only; re-treatment isn't approved.

A positive screen lands hard, then quiets. Parental distress rises in the first weeks and settles over months; a year out it typically sits below the worry families carried when they didn't know 6. Day to day the child plays soccer, eats birthday cake, and sees the endocrinologist twice a year. If the family chooses teplizumab, the two-week course is the only visible event, and eighteen months on, when untreated peers were tipping into diabetes, this child is still Stage 2 2. When Stage 3 finally arrives, the supplies are already on the shelf.

Screening is free through TrialNet; teplizumab lists near $194,000 a course, usually covered with prior authorization at Stage 2 8.

The fine print β€” when to skip it, and what people get wrong

"Teplizumab cures T1D." No. It delays onset by a median of a few years; on long follow-up most treated patients develop diabetes anyway 3. Delay is not prevention.

"Screening is only for families with T1D." Relatives are the highest-yield group, but 85–90% of new cases have no family history, which is why general-population pilots exist 7.

Teplizumab is a real immunosuppressant: not in pregnancy, not during active infection, not below age 8 5. Screening carries no such catch, and its DKA benefit applies at any age.

References
  1. 1Ziegler AG, Rewers M, Simell O et al. (2013). Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. link
  2. 2Herold KC, Bundy BN, Long SA et al. (2019). An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine. link
  3. 3Sims EK, Bundy BN, Stier K et al. (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science Translational Medicine. link
  4. 4Hummel S, Carl J, Friedl N et al. (2023). Children diagnosed with presymptomatic type 1 diabetes through public health screening have a low rate of diabetic ketoacidosis at clinical onset. Diabetologia. link
  5. 5FDA (2022). FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes. link
  6. 6Hummel S, PflΓΌger M, Kreichauf S et al. (2017). Psychological impact of childhood islet autoantibody testing in families participating in the Fr1da study. Diabetic Medicine. link
  7. 7Ziegler AG, Kick K, Bonifacio E et al. (2020). Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA. link
  8. 8ICER (2023). Teplizumab for the Prevention of Type 1 Diabetes: Effectiveness and Value β€” Final Evidence Report. link
Related in the handbook (4)
Related
  • β€” Type 1 diabetes and celiac cluster in the same families. A celiac diagnosis is a nudge to know your own T1D risk.
  • β€” For someone with autoantibodies flagged by T1D screening, a CGM is an early-warning tool for the onset of diabetes.
  • β€” For a first-degree relative of someone with type 1 diabetes, a free antibody screen catches the attack years before symptoms.
  • β€” This is type 1 β€” an autoimmune attack you can screen for and delay β€” not type 2, a different disease with a different playbook.
Β·
145